StartsideSGEN • BMV
add
Seagen
Forrige sluttkurs
3 711,48 $
Årsintervall
3 711,48 $ - 3 711,48 $
Markedsverdi
43,15 mrd. USD
P/E-tall
-
Utbytte
-
Markedsnyheter
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(USD) | sep. 2023info | Endring år til år |
---|---|---|
Omsetning | 648,65 mill. | 27,11 % |
Driftskostnader | 262,69 mill. | 24,86 % |
Nettoomsetning | −215,79 mill. | −13,09 % |
Netto resultatmargin | −33,27 | 11,02 % |
Fortjeneste per aksje | −1,15 | −11,65 % |
EBITDA | −209,33 mill. | −19,47 % |
Faktisk avgiftssats | 0,26 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
(USD) | sep. 2023info | Endring år til år |
---|---|---|
Kontant / kortsiktige inv. | 1,24 mrd. | −29,86 % |
Totale aktiva | 3,63 mrd. | 0,42 % |
Totale passiva | 1,08 mrd. | 35,94 % |
Total egenkapital | 2,55 mrd. | — |
Utestående aksjer | 188,66 mill. | — |
P/B-forhold | 274,52 | — |
Avkastning på aktiva | −16,01 % | — |
Avkastning på kapital | −21,12 % | — |
Kontantstrøm
Netto kontantstrøm
(USD) | sep. 2023info | Endring år til år |
---|---|---|
Nettoomsetning | −215,79 mill. | −13,09 % |
Kontantstrøm fra drift | −35,82 mill. | 58,21 % |
Kontanter fra investering | 142,49 mill. | 119,31 % |
Kontanter fra finansiering | 15,52 mill. | −15,59 % |
Netto kontantstrøm | 119,90 mill. | 1 958,05 % |
Fri kontantstrøm | 71,52 mill. | 1 141,10 % |
Om
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Administrerende direktør
Grunnlagt
15. juli 1997
Hovedkvarter
Nettsted
Ansatte
3 256